Cargando…
Nanocarrier Lipid Composition Modulates the Impact of Pulmonary Surfactant Protein B (SP-B) on Cellular Delivery of siRNA
Two decades since the discovery of the RNA interference (RNAi) pathway, we are now witnessing the approval of the first RNAi-based treatments with small interfering RNA (siRNA) drugs. Nevertheless, the widespread use of siRNA is limited by various extra- and intracellular barriers, requiring its enc...
Autores principales: | Guagliardo, Roberta, Merckx, Pieterjan, Zamborlin, Agata, De Backer, Lynn, Echaide, Mercedes, Pérez-Gil, Jesus, De Smedt, Stefaan C., Raemdonck, Koen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781292/ https://www.ncbi.nlm.nih.gov/pubmed/31450805 http://dx.doi.org/10.3390/pharmaceutics11090431 |
Ejemplares similares
-
Pulmonary surfactant as a versatile biomaterial to fight COVID-19
por: Herman, Lore, et al.
Publicado: (2022) -
Increasing Angiogenesis Factors in Hypoxic Diabetic Wound Conditions by siRNA Delivery: Additive Effect of LbL-Gold Nanocarriers and Desloratadine-Induced Lysosomal Escape
por: Shaabani, Elnaz, et al.
Publicado: (2021) -
Exosomes as nanocarriers for siRNA delivery: paradigms and challenges
por: Shahabipour, Fahimeh, et al.
Publicado: (2016) -
Nanocarriers for delivery of siRNA as gene silencing mediator
por: Morales-Becerril, Aideé, et al.
Publicado: (2022) -
Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment
por: Peng, Yuan, et al.
Publicado: (2018)